Galit Levin
Chief Tech/Sci/R&D Officer at TransPharma Medical Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Yossi Gross | M | 77 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | 24 years |
Larry Ellberger | M | 76 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Ronit Bendori | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Giora Arbel | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Judith Kornfeld | F | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Mario Thomas | M | 73 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Jason Martin | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Zev Sohn | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Hana Gadassi | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Yael Kenan | M | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Ronit Nahary | F | - |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Ruth Alon | F | 71 |
TransPharma Medical Ltd.
TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Doron Myersdorf | M | - |
Technion-Israel Institute of Technology
| 4 years |
Lihu Avitov | M | 53 |
Technion-Israel Institute of Technology
| 7 years |
Ariel Sverdlik | M | 55 |
Technion-Israel Institute of Technology
| 9 years |
Guy Yachin | M | 55 |
Technion-Israel Institute of Technology
| 6 years |
Tsachi Czaczkes | M | - |
Technion-Israel Institute of Technology
| 4 years |
Shmuel Nir | M | 62 |
Technion-Israel Institute of Technology
| 4 years |
Neil Feldman | M | - |
Technion-Israel Institute of Technology
| 4 years |
Eyal Lipetz Eliassi | M | 53 |
Technion-Israel Institute of Technology
| 4 years |
Ophir Herbst | M | 53 |
Technion-Israel Institute of Technology
| 4 years |
Moshe Golani | M | 56 |
Technion-Israel Institute of Technology
| 4 years |
Erez Harel | M | - |
Technion-Israel Institute of Technology
| 4 years |
Gadi Gideon Netzer | M | 59 |
Technion-Israel Institute of Technology
| 4 years |
Gilad Har Oz | M | 53 |
Technion-Israel Institute of Technology
| 4 years |
Shir Goldberg | M | - |
Technion-Israel Institute of Technology
| 4 years |
Ehud Hai | M | - |
Technion-Israel Institute of Technology
| 4 years |
Gideon Yampolsky | M | 62 |
Technion-Israel Institute of Technology
| 4 years |
Amir Moshe Ben David | M | 60 |
Technion-Israel Institute of Technology
| 4 years |
Nir Wolf | M | 58 |
Technion-Israel Institute of Technology
| 4 years |
Eyal Meron | M | 65 |
Technion-Israel Institute of Technology
| 4 years |
David Daniel | M | 54 |
Technion-Israel Institute of Technology
| 2 years |
Oleg Raikhman | M | - |
Technion-Israel Institute of Technology
| 4 years |
Shmuel Assa | M | 55 |
Technion-Israel Institute of Technology
| 4 years |
Niv Ein-Gal | M | - |
Technion-Israel Institute of Technology
| 4 years |
Omri Toppol | M | - |
Technion-Israel Institute of Technology
| 4 years |
Jenik Aviram | M | - |
Technion-Israel Institute of Technology
| 4 years |
Michal Vakrat Wolkin | M | 52 |
Technion-Israel Institute of Technology
| 4 years |
Eyal Cohen | M | 53 |
Technion-Israel Institute of Technology
| 4 years |
Karin Klier Ackerstein | F | 56 |
Technion-Israel Institute of Technology
| 4 years |
Roy Livneh | M | 52 |
Technion-Israel Institute of Technology
| 4 years |
Chaim Schulzman | M | 51 |
Technion-Israel Institute of Technology
| 4 years |
Elena Winefeld | F | - |
Technion-Israel Institute of Technology
| 4 years |
Dganit Vered | F | 57 |
Technion-Israel Institute of Technology
| 4 years |
Lilach Zinger | F | 50 |
Technion-Israel Institute of Technology
| 4 years |
Itzik Baruch | M | - |
Technion-Israel Institute of Technology
| 4 years |
Gilad Shainer | M | - |
Technion-Israel Institute of Technology
| 4 years |
Gilad Frenkel | M | 54 |
Technion-Israel Institute of Technology
| 4 years |
Amit Segev | M | - |
Technion-Israel Institute of Technology
| 4 years |
Guy Miasnik | M | - |
Technion-Israel Institute of Technology
| - |
Eitan Achlow | M | - |
Technion-Israel Institute of Technology
| 4 years |
Boaz Chalamish | M | - |
Technion-Israel Institute of Technology
| 3 years |
Gilad Rosenberg | M | - |
Technion-Israel Institute of Technology
| 4 years |
Yuval Leader | M | - |
Technion-Israel Institute of Technology
| 1 years |
Ronen Lazarovich | M | 54 |
Technion-Israel Institute of Technology
| 4 years |
Yoel Fink | M | - |
Technion-Israel Institute of Technology
| 4 years |
Yaniv Golan | M | - |
Technion-Israel Institute of Technology
| 4 years |
Eitan Shabtay | M | 54 |
Technion-Israel Institute of Technology
| 4 years |
Uzi Zangi | M | - |
Technion-Israel Institute of Technology
| 4 years |
Belly Koren | F | - |
Technion-Israel Institute of Technology
| 4 years |
Adili Tsaba | F | - |
Technion-Israel Institute of Technology
| 4 years |
Ronny Lempel | M | - |
Technion-Israel Institute of Technology
| 4 years |
Itzhak H. Maor | M | - |
Technion-Israel Institute of Technology
| 1 years |
Pinhas Buchris | M | - |
Technion-Israel Institute of Technology
| 3 years |
Michael Chertok | M | - |
Technion-Israel Institute of Technology
| 4 years |
Yuval Mika | M | 66 |
Technion-Israel Institute of Technology
| 5 years |
Miki Elad | M | - |
Technion-Israel Institute of Technology
| 3 years |
Gamliel Shitrit | M | - |
Technion-Israel Institute of Technology
| 4 years |
Arnon Kraft | M | 50 |
Technion-Israel Institute of Technology
| 4 years |
Nurit Tal Shamir | F | 59 |
Technion-Israel Institute of Technology
| 2 years |
Yoav Kimchy | M | 63 |
Technion-Israel Institute of Technology
| 6 years |
Eliezer Lavy | M | 58 |
Technion-Israel Institute of Technology
| 4 years |
Joel Brand | M | - |
Technion-Israel Institute of Technology
| 4 years |
Alexander Avtsin | M | - |
Technion-Israel Institute of Technology
| 4 years |
Arnon Kraemer | M | - |
Technion-Israel Institute of Technology
| 4 years |
Itay Katz | M | - |
Technion-Israel Institute of Technology
| 4 years |
Yossi Netzer | M | 60 |
Technion-Israel Institute of Technology
| 4 years |
Fadi Swidan | M | - |
Technion-Israel Institute of Technology
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Israel | 78 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Galit Levin
- Personal Network